Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable ...

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts ...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor ...

BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
CURE

How Recent Lung Cancer FDA Approvals are Shaping Treatment for Patients

Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations ...
Renal & Urology News

FIND-CKD Results Support Finerenone Use in Nondiabetic CKD Population

Findings from the FIND-CKD trial indicate finerenone may provide a new treatment option for slowing renal function loss in CKD patients without diabetes.

Pfizer Phase 2 Atirmociclib Study Meets Primary Endpoint

Pfizer said a mid-stage study of its investigational CDK4 inhibitor atirmociclib met its key goal in certain patients with breast cancer. Pfizer on Tuesday said the randomized Phase 2 study met its ...
Cadillac News

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
Townsville Bulletin

Racura secures green light for RC220 HARNESS-1 lung cancer trial

Racura Oncology’s lead drug candidate RC220 has cleared an important regulatory hurdle after receiving governance approval ...

Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative

Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ...

'Very Active' Dad, 37, Thought He Had Sore Abs. It Was Stage 4 Colon Cancer

But it wasn't until he started to feel an odd pain that he thought something was off, too. "I started to get a little bit of ...
Las Vegas Sun

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...